Urovysion™ testing can lead to early identification of intravesical therapy failure in patients with high risk non-muscle invasive bladder cancer

Abstract

Purpose: In this study, we investigated the ability of UroVysion TM to assess response to intravesical therapy in patients with high risk superficial bladder tumors. Materials and Methods:We performed a retrospective review of patients undergoing intravesical therapy for high risk superficial bladder tumors. Urine specimens were collected for UroVysion TM analysis before and immediately after a course of intravesical therapy. Cytology and cystoscopy were performed six weeks after treatment, using either a positive cytology or visible abnormality on cystoscopy as a prompt for biopsy. The operating characteristics of the UroVysion TM test were then determined. Results: 41 patients were identified in whom 47 cycles of induction and 41 cycles of maintenance intravesical therapy were given during the study period. This yielded a total of 88 treatment and evaluation cycles. Median follow-up was 9 months per induction (range 1-21 months) and 13 months per patient (range 1-25 months). A total of 133 urine samples were collected for UroVysion TM of which 40 were positive. Based upon standard clinical evaluation, 41 biopsies were performed which detected 20 recurrences. UroVysion TM testing performed immediately upon completion of therapy for the 41 patients undergoing biopsy yielded a sensitivity, specificity, and accuracy of 85%, 61%, and 71%. Conclusions: The use of UroVysion TM following intravesical therapy for high-risk superficial bladder tumors helps to identify patients at high risk of refractory or recurrent disease who should undergo immediate biopsy under anesthesia.

Application of a multiplex urinalysis test for the prediction of intravesical BCG treatment response: A pilot study

“…UroVysion testing was applied at the beginning and the end of the BCG induction cycle (typically involving 6 weekly instillations), and urine cytology and cystoscopy were performed six weeks after cycle completion. In a multivariate analysis, the presence of high-grade disease and a positive UroVysion test after BCG initiation were significant predictors of disease recurrence [ 25 , 26 ]. Again, in these studies, the urine-based results were only informative after the initiation of BCG treatment, and so are not predictive of BCG outcome prior to the first cycle of instillation.…”

High-grade urothelial carcinoma with squamous differentiation metastasizing to the tongue

“…It is now a standard method to identify chromosomal aberrations in urine cytology specimens with prognostic, screening, and predictive utility. [30][31][32][33] The UroVysion kit (Abbott Molecular Inc.) comprises a mixture of four different DNA probes, each with a different flourophore (three centromere probes for chromosomes 3, 7, and 17 and a probe for the 9p21 locus). 34 This, therefore, is designed to detect aneuploidy for chromosomes 3, 7, 17, and loss of the 9p21 which are consistently expressed in UC.…”

Diagnostik und Therapie des Harnblasenkarzinoms

“…[13] analysiert, die die Aussagekraft des UroVysion®-Tests bei Patienten analysiert haben, die sich wegen rezidivierender oberflächlicher Blasentumoren einer intravesikalen Therapie mit BCG unterzogen. Kernaussage der Autoren war, dass dieser Test Patienten frühzeitiger identifizieren kann, die ein Rezidiv entwickeln.…”